obesity

News

Roche claims midstage win for obesity injectable

Roche reports weight loss of up to 22.5% with its injectable GIP/GLP-1 agonist obesity drug, setting up phase 3, but will it be too late to the table?

News

Wegovy pill shows strong early uptake, as rival looms

Encouraging early sales data for oral Wegovy has buoyed Novo Nordisk, as Lilly waits for an FDA decision on its rival orforglipron, now due in Q2.

News

JPM: Novo Nordisk CEO gives insight into new strategy

Novo Nordisk CEO Mike Doustdar covers oral Wegovy, DTC sales channels, and an under-appreciated obesity pipeline in a wide-ranging presentation.

R&D

Obesity, complexity, and the lab: What 2025 taught us, and w...

The complexity of working with the patient population in obesity continues to challenge traditional trial design. hVIVO looks to the year ahead.

News

Study finds weight returns more quickly in GLP-1 users

People who use drugs like GLP-1 agonists to lose weight regain it more quickly than those who use a conventional approach of diet and exercise.

News

Lilly taps Nimbus for another obesity candidate

For a second time, Eli Lilly has turned to Boston biotech Nimbus Therapeutics to add a potential weight loss therapy to its pipeline.

Roche claims midstage win for obesity injectable

Wegovy pill shows strong early uptake, as rival looms

JPM: Novo Nordisk CEO gives insight into new strategy

Obesity, complexity, and the lab: What 2025 taught us, and w...

Study finds weight returns more quickly in GLP-1 users

Lilly taps Nimbus for another obesity candidate

Remepy's hybrid Parkinson's therapy poised for phase 3

Discover a new era of healthcare panel engagement: Grounded ...

obesity

Editor's Picks